The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps

Summary

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in addition to a background treatment of mometasone furcate nasal spray (MFNS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Patients will receive GR1802 injection or Placebo every 2 Weeks.

Timeline

Start

2023-02-08

Primary completion

2024-10-30

Completion

2024-12-30

Drugs

Indications